U-Neuron Biomedical Inc (6973.TWO)
TWD 40.25
(0.5%)
TWD 40.25
(0.5%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -53.2 Million | -36.35 Million | -653 Thousand |
| Net Income | -84.89 Million | -43.17 Million | -11.25 Million |
| Depreciation & Amortization | 6.96 Million | 6.53 Million | 1.64 Million |
| Deferred income taxes | - | - | - |
| Stock-based compensation | 25.09 Million | - | 229 Thousand |
| Change in working capital | -96 Thousand | -876 Thousand | 8.8 Million |
| Other non-cash items | -5.3 Million | -1.65 Million | -676 Thousand |
| Investing Cash Flow | -306.45 Million | 5.19 Million | -88.02 Million |
| Investments in PPE | -2.39 Million | -3.39 Million | -1.85 Million |
| Acquisitions | - | - | - |
| Investment purchases | -434.92 Million | -15 Million | -141 Million |
| Sales/Maturities of investments | 132 Million | 24 Million | 55.66 Million |
| Other Investing Activities | -1.13 Million | -404 Thousand | -827 Thousand |
| Financing Cash Flow | 385.59 Million | 6.65 Million | 137.5 Million |
| Debt repayment | - | - | - |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | 390 Million | 11 Million | 137.5 Million |
| Other Financing Activities | -4.4 Million | - | - |
| Accounts receivables | -268 Thousand | - | - |
| Accounts payables | -265 Thousand | - | - |
| Inventory | -1.29 Million | -2.33 Million | -369 Thousand |
| Other working capital | 1.46 Million | - | - |
| Cash at beginning of period | 31.01 Million | 55.51 Million | 6.69 Million |
| Cash at end of period | 56.95 Million | 31.01 Million | 55.51 Million |
| Capital Expenditure | -2.39 Million | -3.39 Million | -1.85 Million |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | 25.94 Million | -24.5 Million | 48.82 Million |
| Free Cash Flow | -55.59 Million | -39.74 Million | -2.51 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2021 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -32.34 Million | -84.89 Million | -28.82 Million | -56.06 Million | -43.17 Million | -11.25 Million |
| Depreciation & Amortization | 3.94 Million | 6.96 Million | 3.53 Million | 3.42 Million | 6.53 Million | 1.64 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 25.09 Million | - | - | - | 229 Thousand |
| Change in working capital | -8.85 Million | -96 Thousand | 6.98 Million | -7.08 Million | -876 Thousand | 8.8 Million |
| Other non-cash items | 1.32 Million | -5.3 Million | 59 Thousand | 24.75 Million | -1.65 Million | -676 Thousand |
| Investing Cash Flow | 61.47 Million | -306.45 Million | 47.27 Million | -353.72 Million | 5.19 Million | -88.02 Million |
| Investments in PPE | -37.1 Million | -2.39 Million | -1.85 Million | -419 Thousand | -3.39 Million | -1.85 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -26 Million | -434.92 Million | -39.92 Million | -395 Million | -15 Million | -141 Million |
| Sales/Maturities of investments | 125 Million | 132 Million | 90 Million | 42 Million | 24 Million | 55.66 Million |
| Other Investing Activities | 30 Thousand | -1.13 Million | 305 Thousand | -305 Thousand | -404 Thousand | -827 Thousand |
| Financing Cash Flow | -2.38 Million | 385.59 Million | -2.2 Million | 387.79 Million | 6.65 Million | 137.5 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 390 Million | 360 Million | 30 Million | 11 Million | 137.5 Million |
| Other Financing Activities | -2.38 Million | - | -362.2 Million | 357.79 Million | - | - |
| Accounts receivables | -1.68 Million | - | 342 Thousand | -610 Thousand | - | - |
| Accounts payables | 293 Thousand | - | 256 Thousand | -521 Thousand | - | - |
| Inventory | -1.57 Million | -1.29 Million | 359 Thousand | -1.65 Million | -2.33 Million | -369 Thousand |
| Other working capital | -5.88 Million | - | 6.02 Million | -4.29 Million | - | - |
| Cash at beginning of period | 56.95 Million | 31.01 Million | 30.12 Million | 31.01 Million | 55.51 Million | 6.69 Million |
| Cash at end of period | 80.12 Million | 56.95 Million | 56.95 Million | 30.12 Million | 31.01 Million | 55.51 Million |
| Capital Expenditure | -37.1 Million | -2.39 Million | -1.85 Million | -419 Thousand | -3.39 Million | -1.85 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 23.16 Million | 25.94 Million | 26.83 Million | -891 Thousand | -24.5 Million | 48.82 Million |
| Free Cash Flow | -73.02 Million | -55.59 Million | -20.09 Million | -35.38 Million | -39.74 Million | -2.51 Million |
IVT
256150
6846
035150
EKTR4
EGL